SUBSCRIBE
SUBSCRIBE

Don McCormick

Business
Akcea Therapeutics: Ultra-Rare Disease Patients Find Support in Connectedness
Beyond developing novel therapies for serious and rare diseases including FCS, Akcea is also dedicated to supporting the broader needs of the communities they serve.
August 20, 2018
 · 
6 min read
 · 
Don McCormick
IPO letter in the billboard screen
Deals
Three Biotechs Announce IPOs
Three clinical-stage biotechnology companies announced initial public offerings (IPOs) today. Here’s a summary.
June 8, 2018
 · 
2 min read
 · 
Don McCormick
June 8th Research Roundup: Some of the Top Research Stories of the Week
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
June 8, 2018
 · 
3 min read
 · 
Don McCormick
3d illustration of a cancer cell and lymphocytes
Business
Luye to Continue Work with Elpis to Develop New CAR-T Therapies
Luye Pharma Group Ltd., announced today it is expanding its relationship with U.S. biotech firm Elpis Biopharmaceuticals Corp., to work on dual-target based therapies for cancer patients who fail to respond to current treatment.
June 7, 2018
 · 
2 min read
 · 
Don McCormick
Atomwise Awards Support Academic Researchers
Atomwise, Inc., a leader in using artificial intelligence (AI) for drug screening and design, is now accepting applications for their 2018 Artificial Intelligence Molecular Screen (AIMS) awards. The awards support academic researchers in a wide variety of fields, from human and animal health to crop protection.
June 7, 2018
 · 
2 min read
 · 
Don McCormick
Shutterstock.com
Business
Rob Reiner Kicks Off Day 3 of BIO Convention
Actor, director and advocate Rob Reiner opened the third day of the 2018 BIO International Convention.
June 6, 2018
 · 
2 min read
 · 
Don McCormick
Why Amazon Could be More Interested in Medical Dev
Biotech Bay
Cancer Research, Medical Records Targeted by Amazon Mystery Initiative
The secret group within Amazon working on a series of bold projects is starting to become a little less secret.
June 6, 2018
 · 
2 min read
 · 
Don McCormick
Business
Senti Biosciences Brings on Curt Herberts to Help Build New Partnerships
South San Francisco-based Senti Biosciences is getting a new Chief Financial Officer and Chief Business Officer. Former Sangamo Therapeutics Senior Vice President and Chief Business Officer Curt Herberts will join Senti later this month.
June 6, 2018
 · 
1 min read
 · 
Don McCormick
Drug Development
Tricida Files $150M IPO, Shares Kidney Drug Trial Results
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.
June 5, 2018
 · 
2 min read
 · 
Don McCormick
Business
Blueprint and CStone Team Up to Bring Cancer Medicines to China
Blueprint Medicines Corporation and privately held CStone Pharmaceuticals have entered into a partnership to develop and commercialize avapritinib, BLU-554 and BLU-667 in mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies.
June 4, 2018
 · 
2 min read
 · 
Don McCormick
Drug Development
Two Roche Cancer Drugs Get Disappointing Results
Bad news for Roche Holding AG. Two of its cancer drugs, Tecentriq and taselisib, have been shown to provide only modest protection from disease progression.
June 4, 2018
 · 
2 min read
 · 
Don McCormick
Policy
FDA targets abuse of rules to delay entry of generic drugs
FDA Commissioner Scott Gottlieb released a statement on new policies aimed to combat the practice of using certain agency requirements to block timely generic drug entry.
June 1, 2018
 · 
3 min read
 · 
Don McCormick
Business
1Q2018 Earnings Call Highlights Abbott’s $7.4 Billion In Sales
Abbott today announced financial results for the first quarter ending March 31, 2018 and is off to a strong start to the year.
April 18, 2018
 · 
3 min read
 · 
Don McCormick
lawsuit form with filler and book
Policy
Suit Alleges Drug Impurity, Price Fixing as Mallinckrodt Shares Tumble
Amid news of a whistleblower lawsuit, Mallinckrodt Pharmaceuticals (MNK:NYSE) shares dropped 9.51% yesterday.
April 13, 2018
 · 
2 min read
 · 
Don McCormick
Drug Development
Eloxx Pharmaceuticals: Promising Treatment for Rare Genetic Diseases
The people at Eloxx Pharmaceuticals share a common goal — to bring safe and effective therapies to children and adults suffering from rare genetic diseases as quickly as possible.
April 12, 2018
 · 
5 min read
 · 
Don McCormick